Structural basis of mutant-selectivity and drug-resistance related to CO-1686

Non-small-cell lung cancers (NSCLCs) caused by activating mutations in the kinase domain of epidermal growth factor receptor (EGFR) initially respond to first-generation reversible drugs gefitinib and erlotinib. However, clinical efficacy is limited due to the development of drug-resistance that in...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Xiao-E, Zhu, Su-Jie, Liang, Ling, Zhao, Peng, Choi, Hwan Geun, Yun, Cai-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581126/
https://www.ncbi.nlm.nih.gov/pubmed/28881827
http://dx.doi.org/10.18632/oncotarget.18588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581126/
https://www.ncbi.nlm.nih.gov/pubmed/28881827
http://dx.doi.org/10.18632/oncotarget.18588

Ejemplares similares